Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

It features toddler versions of world leaders, including Putin, Trump, Kim, French President Emmanuel Macron and Turkish ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only ...

An employee of the U.S. Department of Health and Human Services sent an email Wednesday that mistakenly included plans to terminate more than 150 research grants related to child and family well ...

People do not develop life-long immunity to the RSV virus. This means they can be infected many times. Bronchiolitis is common during the first 2 years of life. Most children just have coughing and ...

Clayton was just six when he fell ill with the virus that is most deadly in young children. He said it was the 'worst rash' he's ever experienced. 'It's different, because you're itchy,' he said.